Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

This story was originally reported by CNBC. For the complete coverage and latest updates, visit the original source.

Read the full story at CNBC.